Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer

BACKGROUND: Although therapeutic advances have led to enhanced survival in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, detection of residual disease remains challenging. Here, we examine two approved anti-HER2 monoclonal antibodies (mAbs), trastuzumab and pe...

Descripción completa

Detalles Bibliográficos
Autores principales: AghaAmiri, Solmaz, Simien, Jo, Thompson, Alastair M., Voss, Julie, Ghosh, Sukhen C., Hernandez Vargas, Servando, Kim, Sarah, Azhdarinia, Ali, Tran Cao, Hop S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205604/
https://www.ncbi.nlm.nih.gov/pubmed/34194285
http://dx.doi.org/10.1155/2021/5540569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205604/
https://www.ncbi.nlm.nih.gov/pubmed/34194285
http://dx.doi.org/10.1155/2021/5540569

Ejemplares similares